New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis

New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis

The achievements and ongoing efforts of C-Path’s Critical Path to TB Drug Regimens (CPTR) initiative’s work on the Hollow Fiber System Model for Tuberculosis (HFS-TB) are detailed in a new supplement published in the Clinical Infectious Diseases journal. The supplement includes an editorial by the European Medicines Agency (EMA) on its qualification of this tool to reliably assess the potential efficacy of new drugs and combination regimens, an editorial by U.S. Food and Drug Administration (FDA) supporting the use of this tool in drug development, and articles co-authored by members of CPTR’s Preclinical and Clinical Sciences Workgroup. Read it online at http://cid.oxfordjournals.org/content/61/suppl_1.toc.

The HFS-TB provides a deep understanding of how drugs move through the body and exert their pharmacokinetic and pharmacodynamic effect on mycobacterium tuberculosis (MTB). Recognition of this tool as a significant advancement in the development of effective treatments for MTB led to an unexpectedly rapid decision by the EMA to qualify this methodology during the qualification advice stage.